Coronavirus Update - 07th August 2020

We would like to take this opportunity to thank our clients and staff for their continued support over this period of restricted movement. 

We remain open for business as usual and have started welcoming limited numbers of visitors to site

We fully comply with all government guidance on minimising the risks of COVID-19 and have published our risk assessment here

C&EN Article: Former drug companies are becoming CROs

Sean Milmo wrote an article in the August edition (Vo. 96, Iss. 32) of C&EN, discussing the evergrowing trend of Europe's drug industry, looking to increase efficiency and in turn cut costs, raise productivity and focus on more profitable theraputics areas. 

Sean acknowledges that "whole research units are being closed or transferred to new owners that want to economize with fewer employees, but researchers have a reasonable prospect of finding work in an R&D sector that is no longer dominated by pharmaceutical multinationals."

Speaking to Ian Shott on Arcinova, a site which was acquired from Covance in 2016, "we changed the whole business and made 62 people redundant out of a total staff of 112 in the first month,” Shott recalls. “We have since hired 50 scientists and over the next three to four years plan to recruit another 200.”

To download the full article, please click on the link below.

Click here to visit website




Discover how Arcinova can help

We provide a fully integrated approach to drug development, speak to our team and discover how we can help you fast forward to market.

GET IN TOUCH